Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 5/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361527 | 0.85 | PGR (0.55) | PDE4BPGRTDP2S100A4CMA1 | |
| SCHEMBL445935 | 0.82 | MALT1 (0.41) | PDE4BTDP2S100A4CMA1AHR | |
| SCHEMBL30279114 | 0.82 | MALT1 (0.41) | PDE4BTDP2S100A4CMA1AHR | |
| SCHEMBL6937210 | 0.81 | MAPT (0.54) | PGRPBRM1CA1CA2CA7 | |
| SCHEMBL568994 | 0.79 | PGR (0.55) | PGRCA1CA2CA4CA7 | |
| SCHEMBL17922578 | 0.78 | TDP2 (0.46) | PGRTDP2TDP1TGM2CES1 | |
| SCHEMBL7565951 | 0.78 | PGR (0.44) | PGRCA1CA2CA7CA9 | |
| SCHEMBL7880635 | 0.78 | PDE4B (0.46) | PDE4BPGRTDP2S100A4CMA1 | |
| SCHEMBL6562466 | 0.78 | PGR (0.44) | PGRTDP2S100A4CA9TDP1 | |
| SCHEMBL30353273 | 0.78 | PGR (0.44) | PGRTDP2S100A4CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622716-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024112654-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| US-20160272600-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, LLC | 2016-09-22 | — | — | US | disclosed |
| US-20160272600-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, LLC | 2016-09-22 | — | — | US | disclosed |
| EP-2406240-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2015-12-23 | — | — | EP | disclosed |
| US-9212153-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-5728846-A | RETENOIDS, RETINOID ACTIVITY; AGONISTS, ANTAGONISTS | ALLERGAN (US) | 1998-03-17 | — | — | US | disclosed |
| US-5723666-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0661259-B1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL MYERS SQUIBB CO (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5648385-A | TREATING RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5618839-A | Retinoid-like compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| WO-1997009297-A2 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | VISION PHARMACEUTICALS L.P. (US) | 1997-03-13 | — | — | WO | disclosed |
| US-5514690-A | Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline | E. R. SQUIBB & SONS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0661259-A1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-05 | — | — | EP | disclosed |
| EP-0610553-A1 | Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline | E.R. SQUIBB & SONS, INC. (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0321175-A1 | Indane derivatives | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | PDE4B 698/4885PGR 2001/4885TDP2 2954/4885 |
| US-20160272600-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | PDE4B 770/4885PGR 4426/4885TDP2 701/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | PDE4B 698/4885PGR 2001/4885TDP2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.